NanoViricides NV-387 Granted Orphan Drug Designation
NanoViricides announced that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an Orphan Drug Designation, ODD, by the US FDA Office of Orphan Products Development, OOPD.
Trade with 70% Backtested Accuracy
Analyst Views on NNVC
About NNVC
About the author
NanoViricides Gains Orphan Drug Designation, Shares Surge 17%
- Orphan Drug Designation: NanoViricides' antiviral candidate NV-387 has received Orphan Drug Designation from the U.S. FDA, a significant milestone that provides key development incentives, including tax credits for clinical trials and potential market exclusivity, which is expected to expedite its regulatory pathway for measles treatment.
- Positive Market Reaction: Following the announcement of the Orphan Drug Designation, NanoViricides' shares surged 17% on Monday, reflecting strong investor confidence in the company's future potential, while the stock has gained 20% over the past 12 months, indicating market recognition of its antiviral products.
- Rare Pediatric Disease Application: The company has also applied for Rare Pediatric Disease Designation for NV-387; if granted, it would make the company eligible for a tradable Priority Review Voucher, historically valued between $150 million and $200 million, providing a significant early revenue source for the company.
- Clinical Trial Preparations: NanoViricides is preparing to initiate a mid-stage trial of NV-387 for mpox in the Democratic Republic of Congo, further validating its effectiveness against multiple human viral infections and enhancing its competitive position in the antiviral treatment market.
NanoViricides Receives Orphan Drug Designation for NV-387
- Orphan Drug Designation: NanoViricides' antiviral drug NV-387 has received Orphan Drug Designation from the US FDA, which qualifies the company for tax credits, user fee exemptions, and seven years of market exclusivity post-approval, thereby accelerating drug development and enhancing competitive positioning.
- Addressing Measles Epidemics: NV-387 is recognized as the only drug candidate demonstrating strong efficacy against the measles virus in animal models, making its development crucial amidst rising global measles cases, particularly in Bangladesh and Guatemala, positioning it as a vital tool against measles resurgence.
- Significant Market Potential: The US reported 1,803 confirmed measles cases in 2026, a notable increase from 2,251 in 2025, highlighting the urgent need for effective treatments; successful development of NV-387 could yield substantial market opportunities and revenue for the company.
- Application for Priority Review Voucher: NanoViricides has also applied for Rare Pediatric Disease Drug (RPDD) designation, which, if granted, would qualify the company for a Priority Review Voucher, potentially generating $150 to $200 million in early revenue, further propelling the development of NV-387.
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
NanoViricides: Fiscal Q3 Earnings Snapshot
Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.
Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.
Biotech Alert: Searches spiking for these stocks today
Surge in Biotech Stock Interest: Several biotech companies, including NanoViricides and Tenaya Therapeutics, are experiencing significant increases in search activity, indicating heightened investor interest in their innovative therapies and clinical developments.
Key Developments in Clinical Trials: Companies like GeoVax Labs and Tonix Pharmaceuticals are advancing their clinical programs, with promising results in vaccine development and pain management therapies, while others like Editas Medicine and TC Biopharm are making strategic moves to enhance their market positions.
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)
Upcoming Earnings Reports: Several high-profile companies, including NVIDIA, Salesforce, and Lululemon, are set to report their quarterly earnings next week, with analysts closely monitoring their performance for insights into the tech and retail sectors.
Analyst Sentiment: While some companies like NVIDIA and Salesforce have positive outlooks from analysts, others like Nordstrom and Lululemon face mixed reviews due to operational challenges and market conditions, impacting their stock ratings.
NanoViricides Gains Orphan Drug Designation, Shares Surge 17%
- Orphan Drug Designation: NanoViricides' antiviral candidate NV-387 has received Orphan Drug Designation from the U.S. FDA, a significant milestone that provides key development incentives, including tax credits for clinical trials and potential market exclusivity, which is expected to expedite its regulatory pathway for measles treatment.
- Positive Market Reaction: Following the announcement of the Orphan Drug Designation, NanoViricides' shares surged 17% on Monday, reflecting strong investor confidence in the company's future potential, while the stock has gained 20% over the past 12 months, indicating market recognition of its antiviral products.
- Rare Pediatric Disease Application: The company has also applied for Rare Pediatric Disease Designation for NV-387; if granted, it would make the company eligible for a tradable Priority Review Voucher, historically valued between $150 million and $200 million, providing a significant early revenue source for the company.
- Clinical Trial Preparations: NanoViricides is preparing to initiate a mid-stage trial of NV-387 for mpox in the Democratic Republic of Congo, further validating its effectiveness against multiple human viral infections and enhancing its competitive position in the antiviral treatment market.
NanoViricides Receives Orphan Drug Designation for NV-387
- Orphan Drug Designation: NanoViricides' antiviral drug NV-387 has received Orphan Drug Designation from the US FDA, which qualifies the company for tax credits, user fee exemptions, and seven years of market exclusivity post-approval, thereby accelerating drug development and enhancing competitive positioning.
- Addressing Measles Epidemics: NV-387 is recognized as the only drug candidate demonstrating strong efficacy against the measles virus in animal models, making its development crucial amidst rising global measles cases, particularly in Bangladesh and Guatemala, positioning it as a vital tool against measles resurgence.
- Significant Market Potential: The US reported 1,803 confirmed measles cases in 2026, a notable increase from 2,251 in 2025, highlighting the urgent need for effective treatments; successful development of NV-387 could yield substantial market opportunities and revenue for the company.
- Application for Priority Review Voucher: NanoViricides has also applied for Rare Pediatric Disease Drug (RPDD) designation, which, if granted, would qualify the company for a Priority Review Voucher, potentially generating $150 to $200 million in early revenue, further propelling the development of NV-387.
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
NanoViricides: Fiscal Q3 Earnings Snapshot
Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.
Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.
Biotech Alert: Searches spiking for these stocks today
Surge in Biotech Stock Interest: Several biotech companies, including NanoViricides and Tenaya Therapeutics, are experiencing significant increases in search activity, indicating heightened investor interest in their innovative therapies and clinical developments.
Key Developments in Clinical Trials: Companies like GeoVax Labs and Tonix Pharmaceuticals are advancing their clinical programs, with promising results in vaccine development and pain management therapies, while others like Editas Medicine and TC Biopharm are making strategic moves to enhance their market positions.
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)
Upcoming Earnings Reports: Several high-profile companies, including NVIDIA, Salesforce, and Lululemon, are set to report their quarterly earnings next week, with analysts closely monitoring their performance for insights into the tech and retail sectors.
Analyst Sentiment: While some companies like NVIDIA and Salesforce have positive outlooks from analysts, others like Nordstrom and Lululemon face mixed reviews due to operational challenges and market conditions, impacting their stock ratings.
